NCT03294018

Brief Summary

This a prospective study when the clinician decides to use sugammadex, heart rate will be recorded every minute for 15 minutes following its administration. If bradycardia occurs and a clinical decision is made to treat it, the medications and doses used will be recorded.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
276

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 6, 2017

Completed
16 days until next milestone

First Submitted

Initial submission to the registry

September 22, 2017

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 26, 2017

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 10, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 10, 2019

Completed
Last Updated

October 9, 2019

Status Verified

October 1, 2019

Enrollment Period

1.3 years

First QC Date

September 22, 2017

Last Update Submit

October 8, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Bradycardia during sugammadex administration

    intraoperative

Study Arms (1)

Bradycardia during sugammadex administration

Recording any heart rate changes during planned administration of sugammadex.

Other: Recording heart rate changes

Interventions

Recording heart rate changes during planned sugammadex administration.

Bradycardia during sugammadex administration

Eligibility Criteria

AgeUp to 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Male and female 0-18 years old undergoing surgery with anesthetic plan with sugammadex.

You may qualify if:

  • Patient age 0-18 years
  • Anesthetic plan includes NMB reversal with sugammadex

You may not qualify if:

  • Sugammadex not used during the case

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nationwide Children's Hospital

Columbus, Ohio, 43205, United States

Location

MeSH Terms

Conditions

Bradycardia

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Chairman, Professor of Anesthesiology

Study Record Dates

First Submitted

September 22, 2017

First Posted

September 26, 2017

Study Start

September 6, 2017

Primary Completion

January 10, 2019

Study Completion

January 10, 2019

Last Updated

October 9, 2019

Record last verified: 2019-10

Locations